TY - JOUR
T1 - Mass drug administration with high-dose ivermectin and dihydroartemisinin-piperaquine for malaria elimination in an erea of low transmission with high coverage of malaria control interventions: protocol for the MASSIV cluster randomized clinical trial
AU - Dabira, Edgard Diniba
AU - Soumare, Harouna M.
AU - Lindsay, Steven W.
AU - Conteh, Bakary
AU - Ceesay, Fatima
AU - Bradley, John
AU - Kositz, Christian
AU - Broekhuizen, Henk
AU - Kandeh, Balla
AU - Fehr, Alexandra E.
AU - Nieto-Sanchez, Claudia
AU - Muela Ribera, Joan
AU - Grietens, Koen Peeters
AU - Smit, Menno Roderick
AU - Drakeley, Chris
AU - Bousema, Teun
AU - Achan, Jane
AU - D'Alessandro, Umberto
N1 - FTX; DOAJ; GOAA; (CC BY 4.0)
PY - 2020
Y1 - 2020
N2 - Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission.Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions.Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of similar to 2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans.Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission.
AB - Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission.Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria transmission in an area with high coverage of malaria control interventions.Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control and 16 intervention). A buffer zone of similar to 2 km was created around all intervention clusters. MDA with IVM plus DP was implemented in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian National Malaria Control Program plans.Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September 2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence on the impact of MDA with IVM plus DP on malaria transmission.
KW - ivermectin
KW - dihydroartemisinin-piperaquine
KW - mass drug administration
KW - malaria
KW - cluster randomized trial
KW - The Gambia
KW - PLASMODIUM-FALCIPARUM
KW - CHILDREN
KW - PHARMACOKINETICS
KW - EFFICACY
KW - SAFETY
KW - ADULTS
U2 - 10.2196/20904
DO - 10.2196/20904
M3 - A1: Web of Science-article
SN - 1929-0748
VL - 9
JO - JMIR Research Protocols
JF - JMIR Research Protocols
IS - 11
M1 - 20904
ER -